Abstracts tagged "human leukocyte antigens (HLA) and scleroderma"

Abstract Number: 1120 • 2018 ACR/ARHP Annual Meeting
Strong HLA and Novel Non-HLA Associations Identified By Auto-Antibody Subset Analysis of African Americans with Scleroderma from the Genome Research in African American Scleroderma Patients Cohort
Pravitt Gourh¹, Elaine F. Remmers², Theresa Alexander³, Steven Boyden⁴, Nadia D. Morgan⁵, Ami A. Shah⁶, Maureen D. Mayes⁷, Ayo Doumatey², Amy Bentley², Daniel Shriner⁸, Robyn T. Domsic⁹, Thomas A. Medsger Jr.¹⁰, Virginia D. Steen¹¹, Paula S. Ramos¹², Rick Silver¹³, Benjamin D. Korman¹⁴, John Varga¹⁵, Elena Schiopu¹⁶, Dinesh Khanna¹⁷, Vivien Hsu¹⁸, Jessica K. Gordon¹⁹, Lesley Ann Saketkoo²⁰, Heather Gladue²¹, Brynn Kron²², Lindsey A. Criswell²², Chris T. Derk²³, S. Louis Bridges Jr.²⁴, Victoria Shanmugam²⁵, Kathleen D. Kolstad²⁶, Lorinda Chung²⁷, Reem Jan²⁸, Elana J. Bernstein²⁹, Avram Goldberg³⁰, Marcin Trojanowski³¹, Suzanne Kafaja³², Kathleen Maksimowicz-McKinnon³³, Settara C Chandrasekharappa², Adebowale Adeyemo², Charles Rotimi², Fredrick M. Wigley³⁴, Francesco Boin³⁵ and Daniel L. Kastner³⁶, ¹NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, ⁵Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁸National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, MD, ⁹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁰University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹²Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ¹⁵Northwestern University, Chicago, IL, ¹⁶University of Michigan, Ann Arbor, MI, ¹⁷Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁸Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ¹⁹Rheumatology, Hospital for Special Surgery, New York, NY, ²⁰Tulane, New Orleans, LA, ²¹Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²²University of California San Francisco, San Francisco, CA, ²³Rheumatology, University of Pennsylvania, Philadelphia, PA, ²⁴Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL, ²⁵Rheumatology, The George Washington University, Washington, DC, ²⁶Rheumatology, Stanford University Medical Center, Stanford, CA, ²⁷Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²⁸Medicine, Rheumatology, University of Chicago, Chicago, IL, ²⁹Rheumatology, Columbia University, New York, NY, ³⁰NYU Langone Medical Center, New York, NY, ³¹Boston University, Boston, MA, ³²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³³Rheumatology, Henry Ford Hospital, Detroit, MI, ³⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³⁵Rheumatology, University California, San Francisco, San Francisco, CA, ³⁶Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Anti-fibrillarin (nucleolar, AFA) and anti-topoisomerase I (ATA) autoantibodies are specific to systemic sclerosis (SSc) and are common in African Americans (AA). These autoantibodies define…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].